Development of high-specific-activity 68Ga-labeled DOTA-rhenium-cyclized α-MSH peptide analog to target MC1 receptors overexpressed by melanoma tumors

Nuclear Medicine and Biology

Volumn 36, Issue 5, 2009, Pages 505-513

  Cantorias, Melchor V ^a   Figueroa, Said D ^b,c   Quinn, Thomas P ^b,c   Lever, John R ^b,c   Hoffman, Timothy J ^b   Watkinson, Lisa D ^b,c   Carmack, Terry L ^b,c   Cutler, Cathy S ^a  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Ga 68; HPLC purification; Microwave labeling; PET; Specific activity; Melanocyte stimulating hormone

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID RHENIUM ALPHA INTERMEDIN GA 68; GALLIUM 68; MELANOCORTIN 1 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG SPECIFICITY; EARLY DIAGNOSIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY CLEARANCE; MELANOMA; MICRO-COMPUTED TOMOGRAPHY; MOUSE; MUSCLE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; SKIN; TUMOR LOCALIZATION;

EID: 67349235942     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.01.017     Document Type: Article

References (52)

1. Gray-Schopfer V., Wellbrock C., and Marais R. Melanoma biology and targeted therapy. Nature 445 (2007) 851-857
2. Cancer facts and figures (2007), American Cancer Society, Atlanta (Ga). http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf [Accessed August 16, 2007]
3. Dadachova E., and Casadevall A. Renaissance of targeting molecules for melanoma. Cancer Biother Radio 21 (2006) 545-552
4. Rampen F.H., Casparie-van Velsen J.I., van Huystee B.E., Kiemeney L.A., and Schouten L.J. False-negative findings in skin cancer and melanoma screening. J Am Acad Dermatol 33 (1995) 59-63
5. Tatro J.B., and Reichlin S. Specific receptors for alpha-melanocyte-stimulating hormone are widely distributed in tissues of rodents. Endocrinology 121 (1987) 1900-1907
6. Siegrist W., Solca F., Stutz S., Giuffre L., Carrel S., Girard J., et al. Characterization of receptors for α-melanocyte-stimulating hormone on human melanoma cells. Cancer Res 49 (1989) 6352-6358
7. Ghanem G.E., Comunale G., Libert A., Vercammen-Grandjean A., and Lejeune F.J. Evidence for alpha-melanocyte-stimulating hormone (α-MSH) receptors on human malignant melanoma cells. Int J Cancer 41 (1988) 248-255
8. Jiang J., Sharma S.D., Fink J.L., Hadley M.E., and Hruby V.J. Melanotropic peptide receptors: membrane markers of human melanoma cells. Exp Dermatol 5 (1996) 325-333
9. 111In-labeled DOTA-conjugated rhenium-cyclized α-MSH analogues. J Med Chem 45 (2002) 3048-3056
10. Froidevaux S., Calame-Christe M., Tanner H., Sumanovski L., and Eberle A.N. A novel DOTA-α-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. J Nucl Med 43 (2002) 1699-1706
11. 111In-DTPA-labeled analogues for alpha-melanocyte-stimulating hormone for melanoma targeting: receptor binding in vitro and in vivo. Int J Cancer 58 (1994) 749-750
12. Bard D.R., Knight C.G., and Page-Thomas D.P. A chelating derivative of α-melanocyte stimulating hormone as a potential imaging agent for malignant melanoma. Br J Cancer 62 (1990) 919-922
13. Wraight E.P., Bard D.R., Maughan T.S., Knight C.G., and Page-Thomas D.P. The use of a chelating derivative of alpha-melanocyte stimulating hormone for the clinical imaging of malignant melanoma. Br J Radiol 65 (1992) 112-118
14. Morgensen C.E., and Solling K. Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids. Scand J Clinic Lab Invest 37 (1977) 477-486
15. 1-octreotide. Bioconjug Chem 9 (1998) 192-200
16. 111In-DTPA-e{open}-lysine as the primary metabolic and excretory product. Nucl Med Biol 21 (1994) 1023-1034
17. Silbernagl S. The renal handling of amino acids and oligopeptides. Physiol Rev 68 (1988) 911-1007
18. Duncan J.R., and Welch M.J. Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins. J Nucl Med 34 (1993) 1728-1738
19. Maack T., Johnson V., Kan S.T., Figueiredo J., and Sigulem D. Renal, filtration, transport, and metabolism of low molecular weight proteins: a review. Kidney Int 16 (1979) 251-270
20. 111In-diethylene-triaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo. Cancer Res 55 Suppl (1995) 5714s-5720s
21. Froidevaux S., Calame-Christe M., Tanner H., and Eberle A.N. Melanoma targeting with DOTA-α-melanocyte-stimulating hormone analogs: structural parameters affecting tumor uptake and kidney uptake. J Nucl Med 46 (2005) 887-895
22. 64Cu-labeled alpha-melanocyte-stimulating hormone for microPET imaging of melanocortin 1 receptor expression. Bioconjug Chem 18 (2007) 765-772
23. 99mtechnetium-labeled cyclic α-melanocyte stimulating hormone peptide analogues. Cancer Res 60 (2000) 5649-5658
24. 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int J Cancer 101 (2002) 480-487
25. Giblin M.F., Wang N.N., Hoffman T.J., Jurisson S.S., and Quinn T.P. Design and characterization of α-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc Natl Acad Sci U S A 95 (1998) 12814-12818
26. Miao Y., Hylarides M., Fisher D.R., Shelton T., Moore H., Wester D.W., et al. Melanoma therapy via peptide-targeted α-radiation. Clin Cancer Res 11 (2005) 5616-5621
27. 177Lu-labeled DOTA conjugated α-melanocyte-stimulating hormone in a murine melanoma-bearing mouse model. Cancer Biother Radio 22 (2007) 333-340
28. 68Ga-labeled DOTA-rhenium cyclized α-MSH peptide analog: a potential radiopharmaceutical for PET imaging of malignant melanoma. J Nucl Med 48 Suppl 2 (2007) 21P [Abstract]
29. Froidevaux S., Calame-Christe M., Schumacher J., Tanner H., Saffrich R., Henze M., et al. A gallium-labeled DOTA-α-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med 45 (2004) 116-123
30. 68Ga-EDTA complex. Possible applications in nuclear medicine. Acta Isotopica 11 1 (1971) 17
31. Friedlander G., Kennedy J.W., Macias E.S., and Miller J.M. Nuclear and radiochemistry. 3rd ed. (1981), John Wiley and Sons, New York
32. Cherry S.R., Sorenson, and Phelps M.E. Physics in nuclear medicine. 3rd ed. (2003), Elsevier, Philadelphia
33. 18F- radiopharmacy. Ernst Schering Res Found Workshop 62 PET Chemistry (2007) 215-242
34. Cutler C.S., Giron C.G., Reichert D.E., Snyder A.Z., Herrero P., Anderson C.J., et al. Evaluation of gallium-68 Tris(2-mercaptobenzyl)amine: a complex with brain and myocardial uptake. Nucl Med Biol 26 (1999) 305-316
35. 68Ga bioconjugates with high specific radioactivity. Bioconjug Chem 15 (2004) 554-560
36. Stone-Elander S., and Elander N. Microwave applications in radiolabeling with short-lived positron-emitting radionuclides. J Label Compd Radiopharm 45 (2002) 715-746
37. Hwang D.R., Moerlein S.M., Lang L., and Welch M.J. Application of microwave technology to the synthesis of short-lived radiopharmaceuticals. J Chem Soc (Chem Commun) (1987) 1799-1801
38. 68Ga-labeled peptide. Nucl Med Biol 35 (2008) 529-536
39. 111In-DOTA-rhenium cyclized α-MSH analog: a novel cyclic-peptide analog with improved tumor targeting properties. J Nucl Med 42 (2001) 1847-1855
40. Dymov A.M., and Savostin A.P. Analytical chemistry of gallium (1970), Ann Arbor Science Publishers, Ann Arbor
41. Anderson C.J., and Welch M.J. Gallium. In: Seiler H.G., et al. (Ed). Handbook on metals in clinical and analytical chemistry (1994), Marcel Dekker, Inc., New York 371-380
42. 68Ga-based PET-radiopharmaceuticals at room temperature. Bionconjug Chem 19 (2008) 569-573
43. Wei L., Miao Y., Gallazzi F., Quinn T.P., Welch M.J., Vāvere A.L., et al. Ga-68-labeled DOTA-rhenium-cyclized α-melanocyte-stimulating hormone analog for imaging of malignant melanoma. Nucl Med Biol 34 (2007) 945-953
44. 11), a cyclized peptide analogue of peptide analogue of α-MSH. J Med Chem 48 (2005) 2985-2992
45. Sharma S.D., Jiang J., Hadley M.E., Bentley D.L., and Hruby V.J. Melanotropic peptide-conjugated beads for microscopic visualization and characterization of melanoma melanotropic receptors. Proc Natl Acad Sci U S A 93 (1996) 13715-13720
46. Eberle A.N., and Froidevaux S. Radiolabeled α-melanocyte-stimulating hormone analogs for receptor-mediated targeting of melanoma: from tritium to indium. J Mol Recognit 16 (2003) 248-254
47. Kappe C.O., and Dallinger D. Microwave-assisted synthesis in water as solvent. Chem Rev 107 (2007) 2563-2591
48. Cantorias M.V., Quinn T.P., and Cutler C.S. Synthesis of high specific activity melanoma targeting agents. J Nucl Med 48 Suppl 2 (2007) 315P [Abstract]
49. Okarvi S.M. Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer. Cancer Treat Rev 34 (2008) 13-26
50. 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues. Nucl Med Biol 33 (2006) 723-733
51. 99mTc-labeled α-melanotropin peptides. In: Nicolini M., and Mazzi U. (Eds). Technetium, rhenium, and other metals in chemistry and nuclear medicine (1998), SG Editorial, Padova, Italy 457-463
52. 18F-labeled anti-tac disulfide-stabilized Fv. Cancer Res 58 (1998) 2612-2617